Clinical Trial Update: A Composite Assay for HER2-positive Early-stage Breast Cancer Management

View source ↗

Summary

This clinical trial is evaluating a composite assay for managing HER2-positive early-stage breast cancer and is currently recruiting in Milan, Italy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3), HER2 | Status: RECRUITING